Furthermore, using cell‐specific CCR2 KO transgenic mice (e.g., MSPC‐specific LepR+) and broader immunofluorescence analyses, particularly in bone injury models associated with common comorbidities such as diabetes and osteoporosis, could provide additional insights into the nuanced roles of CCL/R2 signalling in bone repair. This evidence concerns the gene LEPR and diabetes mellitus.